High glucose increases expression of cyclooxygenase-2, increases oxidative stress and decreases the generation of nitric oxide in mouse microvessel endothelial cells

Journal of Cellular Physiology

Volumn 222, Issue 3, 2010, Pages 669-675

  Aljofan, Mohamad ^a   Ding, Hong ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOCYNIN; CAY 10404; CHELERYTHRINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIMER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; INDOMETACIN; MONOMER; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; HYPERGLYCEMIA; MICROVASCULATURE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ACETOPHENONES; ANIMALS; BENZOPHENANTHRIDINES; BLOTTING, WESTERN; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOWN-REGULATION; ENDOTHELIAL CELLS; GLUCOSE; HYPERGLYCEMIA; INDOMETHACIN; ISOXAZOLES; MEMBRANE PROTEINS; MICE; MICROVESSELS; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; SULFONES; SUPEROXIDES; TIME FACTORS; UP-REGULATION;

EID: 73649098790     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21986     Document Type: Article

References (48)

1. Aasum E, Cooper M, Severson DL, Larsen TS. 2005. Effect of BM17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 83:183-190.
2. Antman EM, DeMets D, Loscalzo J. 2005. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112:759-770.
3. Ayalasomayajula SP, Kompella UB. 2003. Celecoxib a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 458:283-289.
4. Bohlen HG. 2004. Mechanisms for early microvascular injury in obesity and type II diabetes. Curr Hypertens Rep 6:60-65. Review.
5. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM. 2005. Endothelial nitric oxide synthase dysfunction in diabetic mice: Importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48:1933-1940.
6. Cohen RA, Plane F, Najibi S, Huk I, Malinski T, Garland CJ. 1997. Nitric oxide is the mediator of both endothelium-dependent relaxation and hyperpolarization of the rabbit carotid artery. Proc Natl Acad Sci USA 94:4193-4198.
7. Cosentino F, Eto M, De Paolis P, van der Loo B, BachschmidM, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, Luscher TF. 2003. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: Role of protein kinase C and reactive oxygen species. Circulation 107:1017-1023.
8. The Diabetes Control And Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986.
9. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. 2000. Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974.
10. Ding H, Hashem M, Wiehler WB, Lau W, Martin J, Reid J, Triggle C. 2005. Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse. Br J Pharmacol 146:1110-1118.
11. Ding H, Aljofan M, Triggle CR. 2007. Oxidative stress and increased eNOS and NADPH oxidase expression in mouse microvessel endothelial cells. J Cell Physiol 212:682-689.
12. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. 2001. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348.
13. Du Y, Sarthy VP, Kern TS. 2004. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 287:R735-R741.
14. Egan K, FitzGerald GA. 2006. Eicosanoids and the vascular endothelium. Handb Exp Pharmacol 176:189-211. Review.
15. Feletou M, Vanhoutte PM. 2006. Endothelial dysfunction: A multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 291:H985-H1002.
16. Gendron ME, Thorin-Trescases N, Villeneuve L, Thorin E. 2007. Aging associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial dysfunction. Am J Physiol Heart Circ Physiol 292:H451-H458.
17. Giardino R, Giavaresi G, Fini M, Torricelli P, Guzzardella GA. 2002. The role of different chemical modifications of superoxide dismutase in preventing a prolonged muscular ischemia/ reperfusion injury. Artif Cells Blood Substit Immobil Biotechnol 30:189-198.
18. Gimbrone MA, Jr., Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. 2000. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci 902:230-239; discussion 239-240. Review.
19. Grosser T, Fries S, FitzGerald GA. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116:4-15. Review.
20. Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. 1993. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem 268:23448-23454.
21. Hermann M, Camici G, Fratton A, HurlimannD, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F. 2003. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108:2308-2311.
22. Heumüller S,Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schröder K, Brandes RP. 2008. Apocynin is not an inhibitor of vascularNADPHoxidases but an antioxidant. Hypertension 51:211-217.
23. Hink U, Li H, Mollnau H, Oelze M, Matheis E,HartmannM, et al. 2001. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88:E14-E22.
24. IadecolaC, Gorelick PB. 2005. The Janus face of cyclooxygenase-2 in ischemic stroke: Shifting toward downstream targets. Stroke 36:182-185.
25. Ihlemann N, Rask-Madsen C, Perner A, Dominguez H, Hermann T, Kober L, et al. 2003. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am J Physiol Heart Circ Physiol 285:H875-H882.
26. Kang KB, Van Der Zypp A, Iannazzo L, Majewski H. 2006. Age-related changes in monocyte and platelet cyclooxygenase expression in healthy male humans and rats. Transl Res 148:289-294.
27. Kang KB, Rajanayagam MA, van der Zypp A, Majewski H. 2007. A role for cyclooxygenase in aging-related changes of beta-adrenoceptor-mediated relaxation in rat aortas. Naunyn Schmiedebergs Arch Pharmacol 375:273-281.
28. Matz RL, SchottC, Stoclet JC, AndriantsitohainaR. 2000. Age-related endothelial dysfunction with respect to nitric oxide, endothelium-derived hyperpolarizing factor and cyclooxygenase products. Physiol Res 49:11-18. Review.
29. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. 1999. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277.
30. Ng ESM, Cheng ZJ, Ellis E, Ding H, Jiang YF, Li J, Hollenberg MD, Triggle CR. 2007. Nitrosothiol stores in vascular tissue: Modulation by ultraviolet light, acetylcholine and ionomycin. Eur J Pharmacol 560:183-192.
31. Pannirselvam M, Wiehler WB, Anderson T, Triggle CR. 2005. Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. Br J Pharmacol 144:953-960.
32. Persaud SJ, Burns CJ, Belin VD, Jones PM. 2004. Glucose-induced regulation of COX-2 expression in human islets of Langerhans. Diabetes 53:S190-S192.
33. Pop-Busui R, Sima A, Stevens M. 2006. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 22:257-273.
34. Räthel TR, Leikert JF, Vollmar AM, Dirsch VM. 2003. Application of 4,5-diaminofluorescein to reliably measure nitric oxide released from endothelial cells in vitro. Biol Proced Online 5:136-142.
35. Shanmugam N, Todorov IT, Nair I, Omori K, Reddy MA, Natarajan R. 2006. Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct-specific receptor (AGER), and in islets from diabetic mice. Diabetologia 49:100-107.
36. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R. 2000. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97:10197-10202.
37. Sun D, Liu H, Yan C, Jacobson A, Ojaimi C, Huang A, Kaley G. 2006. COX-2 contributes to the maintenance of flow-induced dilation in arterioles of eNOS-knockout mice. Am J Physiol Heart Circ Physiol 291:H1429-H1435.
38. Taglialatela M, Pannaccione A, Cataldi M, Castaldo P, Secondo A, Iossa S, Di Renzo GF, Annunziato L. 2001. 'Janus face' of nitric oxide action on plasma membrane and intracellular ionic channels. Arch Gerontol Geriatr Suppl 7:379-394.
39. Tesfamariam B. 1994. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 16:383-391.
40. Tesfamariam B, Cohen RA. 1992. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 263:H321-H326.
41. Tomida T, Numaguchi Y, Nishimoto Y, Tsuzuki M, Hayashi Y, Imai H, Matsui H, Okumura K. 2003. Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats. J Hypertens 21:601-609.
42. Topper JN, Cai J, Falb D, Gimbrone MA, Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively upregulated by steady laminar shear stress. 1996. Proc Natl Acad Sci USA 93:10417-10422.
43. Touyz RM. 2008. Apocynin, NADPH oxidase, and vascular cells: A complex matter. Hypertension 51:172-174.
44. UK Prospective Diabetes Study (UKPDS) Group. 1991. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34:877-890.
45. Valeri C, Pozzilli P, Leslie D. 2004. Glucose control in diabetes. Diabetes Metab Res Rev 20:S1-S8. Review.
46. Vásquez-Vivar J, Kalyanaraman B, Martásek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA, Jr. 1998. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc Natl Acad Sci USA 95:9220-9225.
47. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. 2001. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 104:2879-2882.
48. Virdis A, Colucci R, Fornai M, Blandizzi C, Duranti E, Pinto S, Bernardini N, Segnani C, Antonioli L, Taddei S, Salvetti A, Del Tacca M. 2005. Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: Role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 312:945-953.